Find disease awareness content and relevant supporting materials
Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
B-cell receptor pathway inhibitors (BCRis) have transformed treatment of chronic lymphocytic leukemia (CLL); however, the efficacy of therapies for patients whose disease is refractory to/relapses after (R/R) BCRis is unknown.
Efficacy of venetoclax in relapsed chronic lymphocytic leukemia is influenced by disease and response variables
To define the efficacy of venetoclax with extended follow-up and identify clinical or biological treatment-effect modifiers, updated data for previously treated patients with chronic lymphocytic leukemia (CLL) or small lymphocytic...
Impact of Venetoclax Exposure on Clinical Efficacy and Safety in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia.
Venetoclax is a selective, potent, first-in-class B-cell lymphoma-2 inhibitor that restores apoptosis in cancer cells and has demonstrated efficacy in a variety of hematological malignancies.
Efficacy of venetoclax monotherapy in patients with relapsed chronic lymphocytic leukaemia in the post-BCR inhibitor setting: a UK wide analysis.
Venetoclax is a BCL2 inhibitor with activity in relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL). We conducted a multi?centre retrospective analysis of 105 R/R CLL patients who received venetoclax...
Results of Phase III Murano trial of Venclexta + Rituxan in chronic lymphocytic leukaemia published in NEJM.- AbbVie/Roche/Genentech.
Results from the Phase III Murano trial of Venclexta (venetoclax) from AbbVie, and Rituxan (rituximab), from Roche/Genentech, significantly improved progression-free...